Hawaii will receive $1.2 million of a $100 million civil settlement against Abbott Laboratories Inc. over allegations that the global health care company marketed a prescription drug for uses not approved by the U.S. Food and Drug Administration, the state Office of Consumer Protection said Monday.

The state said the money will go into a fund for consumer protection actions.

Sharing in the settlement are 44 other states and the District of Columbia.

The $100 million is part of $1.6 billion Abbott agreed to pay Monday in criminal fines, forfeitures and civil penalties to the federal and state governments over its marketing of the neurological drug Depakote.

The drug is approved to treat epileptic seizures and bipolar mania and to prevent migraines.

Abbott pleaded guilty to misbranding Depakote by promoting it to control agitation and aggression in elderly dementia patients and to treat schizophrenia.

The U.S. Department of Justice said Abbott admitted that from 1998 through 2006 the company maintained a specialized sales force trained to market Depakote in nursing homes and paid pharmacies rebates based on the increased use of the drug in nursing homes they serviced.

The state has no evidence of death or injury caused by the improper use of Depakote in Hawaii, said Lisa Tong of the Office of Consumer Protection.